Image Source: PixabayAfter a pretty sharp slide from the end of July to mid-October, the 5 constituents in the munKNEE Psychedelic Drug Stocks Index are bouncing – up 22% on average last week. Here’s how they rank, in descending order, according to their performances last week, along with any pertinent news affecting that performance.
- is primarily focused on the use of LSD and MNMA. Go here for much more extensive information on LSD and here for much more extensive information on MNMA.
- Read: MindMed Reports Third Quarter 2023 Financial Results and Business Highlights
- is focused on the use of ketamine, DMT and ibogaine. Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
- Read: atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights
- is primarily focused on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine.
- Read: GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates
- is focused on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
- Read: Compass Pathways PLC (CMPS) Reports Q3 2023 Financial Results and Business Highlights
- is researching and developing therapies and products with the world’s largest portfolio of medicinal cannabinoid and psychedelic pharmaceutical products.
SummaryThe munKNEE Psychedelic Drug Stocks Index was up 22.0% last week (down 6.5% the previous week) and is now down 18.1% YTD.More By This Author:Cannabis Investors Have Thrown In The Towel: American MSOs Down 21% This Week
AI Bubble Pricked: Top 11 Stocks Down 7.6% MTD; Still +165% YTD
Quantum Computing Hardware Developers Index Down 7% MTD; Now Only +1% YTD
